Table 1. Baseline characteristics of patients included in the pharmacogenomic analysis.

		Clinical response			TTP		OS
Variables	n (%)	Responder (CR+PR+SD>6 months)	Non-responder (SD <6 months)	P a	Median (95% CI)	P b	Median (95% CI)	P b
Age (years; range)	58 (37–75)	n (%)	n (%)
<60	35 (56.5)	25 (71)	10 (29)	0.55	12 (8.1–15.8)	0.69	29 (14.5–43.6)	0.79
⩾60	27 (43.5)	20 (80)	5 (20)		12 (10.9–13.2)		24 (21–27)
Gender
Male	45 (75)	33 (73)	12 (27)	0.74	12 (10.9–13.2)	0.9	27 (17.6–36)	0.38
Female	15 (25)	12 (80)	3 (20)		9.8 (3.3–16.4)		24 (7.3–41.5)
ECOG performance status
0–1	54 (90)	39 (72)	15 (28)	0.26	12 (10.4–13.5)	0.79	27 (17.2–36.7)	0.31
2	6 (10)	6 (100)	—		12 (8.7–15)		15 (0.0–34.3)
Köhne risk classification
Low	26 (43)	22 (85)	4 (15)	0.04	15 (8.7–21.2)	0.001	35.7 (—)	0.001
Intermediate	28 (47)	21 (75)	7 (25)		11 (7.7–14.9)		24 (18.5–29.1)
High	6 (10)	2 (33)	4 (67)		3 (1.3–5.1)		5 (3–6.8)
Primary tumour site
Colon	41 (68)	28 (68)	13 (32)	0.11	12 (9.2–14.6)	0.33	24 (21.3–27.4)	0.09
Rectum	19 (31)	17 (89)	2 (11)		13 (10.5–15.4)		43 (25.1–61.4)
Previous radiotherapy	6 (10)	5 (83)	1 (17)	1	8 (5.3–9.8)	0.23	18 (16.1–29.6)	0.9
Previous adjuvant chemotherapy	12 (20)	10 (83)	2 (17)	0.71	9.8 (4.6–15.1)	0.31	19 (9.1–29.5)	0.9
Consolidation
Yes	28 (48)	—	—	—	17 (12.2–21.4)	0.001	56 (32.9–79)	0.001
No	30 (52)	—	—		7 (5.8–7.6)		14 (5.1–22.7)
Dose reduction	16 (27)	11 (69)	5 (31)	0.51	12 (4.8–19.2)	0.46	24 (12.7–35.8)	0.31
Dose delay	21 (35)	14 (67)	7 (33)	0.35	9.8 (2.2–17.4)	0.15	18 (4.8–31.9)	0.21

Abbreviations: CI=confidence interval; CR=complete response; ECOG=Eastern Cooperative Oncology Group; OS=overall survival; PR=partial remission; SD=stable disease.

^aClinical response calculated from χ²-test. Kaplan–Meier estimates of TTP and OS.

^bDifference of the estimates tested using the log-rank test.